Psyched Wellness | Investors



Find Psyched Wellness on These Exchanges

Psyched Wellness is led by a strong team of experts, and currently engaged in Pre-Clinical Trials of AME-1, its proprietary extract of Muscimol.


Canada - CSE






Capital Structure

Common Shares135,514,695
Fully Diluted Issued and Outstanding172,276,060

The company has identified a path to market and is on track to commence commercialization of AME-1 derived products for the first half of 2022.

Stock Quote & Chart


Why Invest in Psyched Wellness?


First to Market

Psyched Wellness is the first company to bring the Amanita Muscaria to the market for human consumption in a standardized and safe product

Proven Product

The product is backed by science, patented, and trademarked to Psyched Wellness


We plan to have sustainable revenue from 2022 onwards

Psyched Wellness Launch Shoot Product Shot01 00170

Company Overview

Psyched Wellness Ltd. Is a Canadian-based Life Sciences company focused on the research and development of a legal psychedelic mushroom called Amanita Muscaria. The company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.

Corporate Deck

Sedar Profile